Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants

Antiviral Therapy

Volumn 17, Issue 4, 2012, Pages 701-709

  Chen, Chien Hung ^a   Wang, Jing Houng ^a   Lu, Sheng Nan ^a   Hu, Tsung Hui ^a   Hung, Chao Hung ^a   Chang, Min Hui ^a   Changchien, Chi Sin ^a   Lee, Chuan Mo ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; DNA POLYMERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; STRUCTURAL GENE; VIRUS MUTATION;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; BASE SEQUENCE; CLONING, MOLECULAR; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS;

EID: 84861716715     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2074     Document Type: Article

References (36)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745. (Pubitemid 27527771)
2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262:369-370.
3. Chu CM, Liaw YF. Natural history of chronic hepatitis B virus infection: an immunopathological study. J Gastroenterol Hepatol 1997; 12:S218-S222.
4. Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86:1143-1150.
5. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
6. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669-1673. (Pubitemid 28549139)
7. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129-134. (Pubitemid 30432377)
8. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open label pilot study. Lancet 2001; 358:718-723. (Pubitemid 32823401)
9. Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat 2006; 13:250-255.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751. (Pubitemid 44958517)
11. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385-1391. (Pubitemid 43980117)
12. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55:1488-1495. (Pubitemid 44476796)
13. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44:283-290. (Pubitemid 43069209)
14. Chen CH, Wang JH, Lee CM, et al. Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 2006; 11:771-778. (Pubitemid 44497172)
15. Chen CH, Wang JH, Lu SN, et al. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treatedwith adefovir: a 4-year experience. Liver Int 2011; 31:206-214.
16. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297. (Pubitemid 36929407)
17. Yatsuji H, Noguchi C, Hiraga N, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006; 50:3867-3874. (Pubitemid 44684905)
18. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318-1326.
19. Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-coinfected patient. AIDS 2006; 20:2229-2231. (Pubitemid 44684715)
20. Qi X, Xiong S, Yang H, Miller M, Delaney WE, IV. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12:355-362. (Pubitemid 46787980)
21. Gerolami R, Bourliere M, Colson P, et al. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther 2006; 11:1103-1106. (Pubitemid 44955187)
22. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48:747-755.
23. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53:449-454.
24. Ryu HJ, Lee JM, Ahn SH, et al. Comparison of entecavir (ETV) monotherapy and lamivudine (LAM) plus adefovir (ADV) in patients with chronic hepatitis B who have sequentially failed with LAM and ADV. Hepatol Int 2010; 4:PP256.
25. Chen CH, Lee CM, Lu SN, et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004; 41:454-461. (Pubitemid 39158755)
26. Chen CH, Lee CM, Tung WC, et al. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance. J Hepatol 2010; 52:478-485.
27. Mizokami M, Nakano T, Orito E, et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999; 450:66-71. (Pubitemid 29206714)
28. Lee CM, Chen CH, Lu SN, et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003; 38:95-101. (Pubitemid 36152871)
29. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41:1391-1398. (Pubitemid 40770292)
30. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
31. Cho SW, Koh KH, Cheong JY, et al. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance. J Viral Hepat 2010; 17:171-177.
32. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48:99-108. (Pubitemid 351975535)
33. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-2049. (Pubitemid 43816960)
34. Tenney DJ, Pokornowski K, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2:S302-S303.
35. Choe WH, Hong SP, Kim BK, et al. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 2009; 14:985-993.
36. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129:1198-1209. (Pubitemid 41446860)